Search…

Biokang Biologics (688276.SH): Clinical Trial Application for Recombinant Human Anti-Respiratory Syncytial Virus Monoclonal Antibody Injection Combination Formulation Accepted

22/09/2026

Zhito Finance APP News: Baike Biotech (688276.SH) announced that the company recently received the "Notice of Acceptance" from the National Medical Products Administration for the clinical trial application of its recombinant human anti-respiratory syncytial virus monoclonal antibody injection combination preparation (referred to as "RSV antibody").

Latest

2 m ago

Jenscare Scientific-B (09877): JensClip obtains NMPA registration approval and actively advances commercialization

2 m ago

Allied International (01410) subsidiary and CWG plan to jointly develop an integrated agentic AI platform RealRelay.ai, providing vertical-domain AI agents.

3 m ago

Huace Film & TV (300133.SZ) subsidiary plans to contribute RMB 100 million to participate in the Hangzhou Junlian Fund.

6 m ago

Hengjia Financing Leasing (00379.HK) plans to adopt a 2026 share option scheme

7 m ago

According to NBC News, U.S. Secretary of State Rubio said in an interview with the outlet: "We are willing to meet with the Iranian side during the United Nations period. Trump has said he is willing to meet with anyone, but currently no meeting has been arranged between Trump and the Iranian president. Most ships passing through the Strait of Hormuz have not been attacked. Currently about 60% to 70% of oil shipments have resumed, and this proportion is still rising."

See all latest